GlobeNewswire Inc | Sep 3, 2020 09:00AM EDT

September 03, 2020

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWounds Chief Executive Officer, will present at the following investor conferences in September:

2020 Wells Fargo Virtual Healthcare ConferenceDate: September 10, 2020Time: 8:40am ETFormat: Virtual Presentation

H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14, 2020Time: 11:30am ETFormat: Virtual Presentation

Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Monday, September 21, 2020Time: 3:20pm ETFormat: Virtual Presentation

AboutMediWound Ltd.

MediWoundis a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from theEuropean Medicines Agencyas well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWounds second innovative product, EscharExis a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visitwww.mediwound.com.

Contacts: Jeremy FefferBoaz Gur-Lavie Jeremy FefferChief Financial Officer Managing Director, LifeSci AdvisorsMediWound Ltd. 212-915-2568ir@mediwound.com jeremy@lifesciadvisors.com